Angiotensin Converting Enzymes Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region

Description

The global angiotensin converting enzymes (ACE) inhibitors market size is projected to reach US$ 11,831.7 million by 2030, from US$ 8,070.5 million in 2023, at a CAGR of 5.6% during the forecast period 2023-2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 8,070.5 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.60%	2030 Value Projection:	US$ 11,831.7 Mn

Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Share (%), By Region, 2023

Angiotensin Converting Enzymes Inhibitors Market - IMG1

Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.

Market Dynamics

The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.

Key features of the study:

This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market

Detailed Segmentation:

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
- Benazepril
- Perindopril
- Trandfolapril
- Captopril
- Enalapril
- Lisinopril
- Others (Ramipril, etc.)
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication:
- Hypertension
- Coronary Artery Disease
- Heart Failure
- Chronic Kidney Disease
- Scleroderma
- Others (Migraine, etc.)
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration:
- Oral
- Injectable
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East &Africa
Company Profiles:
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
- Other Prominent Players

Product Code: CMI2746

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of hypertension
Growing Research and Development Activities
Increasing Awareness of Cardiovascular Health
- Restraints
Patent Expirations
Side Effects and Safety Concerns
Side Effects and Safety Concerns
- Opportunities
Increasing Awareness of Cardiovascular Health
Personalized medicine
Combination therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn )
Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
GCC
Israel
North Africa
Central Africa
Rest of Middle East & Africa

10. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
Merck & Co.
AstraZeneca
Sanofi
Boehringer Ingelheim
GlaxoSmithKline
Lupin Limited
Torrent Pharmaceuticals Ltd.
Reddy's Laboratories Ltd.
Mylan
Analyst Views

11. Section

Research Methodology
About us